Oral surveillance and JAK inhibitor safety: the theory of relativity

The published results of the post-marketing ORAL Surveillance study, which compared the Janus kinase (JAK) inhibitor tofacitinib with anti-TNF therapy in older patients with rheumatoid arthritis who have cardiovascular risk factors, have led to changes in the recommendations for the use of JAK inhib...

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin L., Cohen, Stanley B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939241/
https://www.ncbi.nlm.nih.gov/pubmed/35318462
http://dx.doi.org/10.1038/s41584-022-00767-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8939241/
https://www.ncbi.nlm.nih.gov/pubmed/35318462
http://dx.doi.org/10.1038/s41584-022-00767-7

Ejemplares similares